Effects of bone marrow-derived mesenchymal stem cells on doxorubicin-induced liver injury in rats

Doxorubicin (DOX) is a potent chemotherapeutic agent and has toxic effects on various organs, including the liver. In the current study, we aimed to investigate the effects of bone-marrow-derived mesenchymal stem cell (BM-MSC) administration on DOX-induced hepatotoxicity in rats. 24 Wistar-albino rats were divided into three groups: Control, DOX, and DOX+MSC. DOX (20 mg/kg) was administered to the DOX group. In the DOX + MSC group, BM-MSCs (2 x 10(6)) were given through the tail vein following DOX administration. DOX administration led to significant structural liver injury. Besides this, oxidative balance in the liver was impaired following DOX administration. DOX administration also led to an increase in apoptotic cell death in the liver. Structural and oxidative changes were significantly alleviated with the administration of BM-MSCs. Furthermore, BM-MSC administration suppressed excessive apoptotic cell death. Our findings revealed that BM-MSC administration may alleviate DOX-induced liver injury via improving the oxidative status and limiting apoptotic cell death in the liver tissue.